Figure 1.
Best percentage change from baseline in the SPD of target lesions for all 106 patients treated with orelabrutinib.

Best percentage change from baseline in the SPD of target lesions for all 106 patients treated with orelabrutinib.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal